Literature DB >> 1400969

In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.

L L Dever1, J H Jorgensen, A G Barbour.   

Abstract

The susceptibility of Borrelia burgdorferi, the causative agent of Lyme borreliosis, to various antimicrobial agents varies widely among published studies. These differences are probably due in part to variations in susceptibility testing techniques and growth endpoint determinations. We developed a microdilution method for determining the MICs of antibiotics against B. burgdorferi. The method incorporated BSK II medium, a final inoculum of 10(6) cells per ml, and a 72-h incubation period and was found to be simple and highly reproducible. A variety of antibiotics and strains of B. burgdorferi and one strain of Borrelia hermsii were examined by this method. MICs of penicillin, ceftriaxone, and erythromycin for the B31 strain of B. burgdorferi were 0.06, 0.03, and 0.03 microgram/ml, respectively. We compared the MICs obtained by the microdilution method with those obtained by a macrodilution method using similar criteria for endpoint determinations and found the values obtained by both methods to be in close agreement. To further investigate the bactericidal activities of penicillin, ceftriaxone, and erythromycin against strain B31, we used subsurface plating to determine MBCs and we also performed time-kill studies. The MBCs of penicillin, ceftriaxone, and erythromycin were 0.125, 0.03, and 0.06 micrograms/ml, respectively. Time-kill curves demonstrated a greater than or equal to 3-log10-unit killing after 72 h with penicillin, ceftriaxone, and erythromycin; ceftriaxone provided the greatest reduction in CFU. The described methods offer a more standardized and objective approach to susceptibility testing of B. burgdorferi.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400969      PMCID: PMC270500          DOI: 10.1128/jcm.30.10.2692-2697.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

Review 1.  A perspective on the treatment of Lyme borreliosis.

Authors:  B J Luft; P D Gorevic; J J Halperin; D J Volkman; R J Dattwyler
Journal:  Rev Infect Dis       Date:  1989 Sep-Oct

2.  [Identification of Borrelia isolated in the USSR from Ixodes persulcatus Schulze ticks].

Authors:  V N Kriuchechnikov; E I Korenberg; S V Shcherbakov; Iu V Kovalevskiĭ; M L Levin
Journal:  Zh Mikrobiol Epidemiol Immunobiol       Date:  1988-12

3.  Variation in a major surface protein of Lyme disease spirochetes.

Authors:  A G Barbour; S L Tessier; S F Hayes
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

4.  Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.

Authors:  G G Jackson; L J Riff
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

6.  Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythema chronicum migrans.

Authors:  B W Berger; M H Kaplan; I R Rothenberg; A G Barbour
Journal:  J Am Acad Dermatol       Date:  1985-09       Impact factor: 11.527

7.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  Action of penicillin on Borrelia hermsii.

Authors:  A G Barbour; W J Todd; H G Stoenner
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

9.  Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.

Authors:  A C Steere; A R Pachner; S E Malawista
Journal:  Ann Intern Med       Date:  1983-12       Impact factor: 25.391

10.  Colony formation and morphology in Borrelia burgdorferi.

Authors:  T J Kurtti; U G Munderloh; R C Johnson; G G Ahlstrand
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

View more
  41 in total

1.  parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.

Authors:  Kendal M Galbraith; Amanda C Ng; Betsy J Eggers; Craig R Kuchel; Christian H Eggers; D Scott Samuels
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  DhhP, a cyclic di-AMP phosphodiesterase of Borrelia burgdorferi, is essential for cell growth and virulence.

Authors:  Meiping Ye; Jun-Jie Zhang; Xin Fang; Gavin B Lawlis; Bryan Troxell; Yan Zhou; Mark Gomelsky; Yongliang Lou; X Frank Yang
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

Review 3.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

4.  Correlation between plasmid content and infectivity in Borrelia burgdorferi.

Authors:  J E Purser; S J Norris
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.

Authors:  L L Dever; C V Torigian; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy.

Authors:  Klaus-Peter Hunfeld; Eva Ruzic-Sabljic; Douglas E Norris; Peter Kraiczy; Franc Strle
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Phosphoenolpyruvate Phosphotransferase System Components Modulate Gene Transcription and Virulence of Borrelia burgdorferi.

Authors:  Bijay K Khajanchi; Evelyn Odeh; Lihui Gao; Mary B Jacobs; Mario T Philipp; Tao Lin; Steven J Norris
Journal:  Infect Immun       Date:  2015-12-28       Impact factor: 3.441

8.  Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.

Authors:  L L Dever; J H Jorgensen; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

9.  Ultrastructure of Borrelia burgdorferi after exposure to benzylpenicillin.

Authors:  M Schaller; U Neubert
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

10.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.